Frazier Life Sciences Management, L.P. — Quarter-over-Quarter 13F Allocation Shifts Q1 2026
In Q1 2026, Frazier Life Sciences Management, L.P. initiated 4 new positions, increased allocation to 8 existing positions, trimmed 9 positions, and exited 6 positions entirely. The fund's 13F equity book grew from $3.72B to $3.89B (+4.4% QoQ) . All deltas are sourced from sequential SEC Form 13F-HR filings; share-count changes reflect explicit trading activity, while weight changes can also include price movement. This page lists every position change reported — the portfolio overview shows a summary of the top shifts.
Net Portfolio Value Change
- $3.72BPrior quarter
- $3.89BCurrent quarter
- + $0.16BNet delta
- +4.4%% change
New Position Initiations Q1 2026
Securities disclosed for the first time in Q1 2026 that were not present in the prior 13F-HR filing.
| Company | Ticker | Initial Allocation Weight | History |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INC | BCRX | 0.98% | Holders → |
| ACLARIS THERAPEUTICS INC | ACRS | 0.48% | Holders → |
| MONTE ROSA THERAPEUTICS INC | GLUE | 0.42% | Holders → |
| XILIO THERAPEUTICS INC | XLO | 0.09% | Holders → |
Largest Allocation Increases Q1 2026
Largest portfolio-weight increases in existing positions. Share-count delta is shown separately so price-only re-weighting can be distinguished from active adds.
| Company | Ticker | Δ Weight | Δ Shares | History |
|---|---|---|---|---|
| MANNKIND CORP | MNKD | +-0.27% | +39.64% | Holders → |
| IMMUNOCORE HOLDINGS PLC | IMCR | +0.02% | +25.99% | Holders → |
| CYTOKINETICS INC | CYTK | +0.37% | +24.10% | Holders → |
| PALVELLA THERAPEUTICS INC NE | PVLA | +0.80% | +22.15% | Holders → |
| MIRUM PHARMACEUTICALS INC | MIRM | +3.84% | +13.02% | History → |
| ACADIA PHARMACEUTICALS INC. | ACAD | +-0.11% | +10.87% | Holders → |
| ERASCA INC | ERAS | +8.00% | +8.56% | History → |
| DISC MEDICINE INC | IRON | +-0.46% | +7.53% | Holders → |
Largest Allocation Reductions Q1 2026
Largest portfolio-weight decreases in existing positions (positions kept open at a lower allocation).
| Company | Ticker | Δ Weight | Δ Shares | History |
|---|---|---|---|---|
| REVOLUTION MEDICINES INC | RVMD | -0.02% | -15.27% | Holders → |
| AUTOLUS THERAPEUTICS LTD | AUTL | -0.09% | -3.79% | Holders → |
| TREVI THERAPEUTICS INC | TRVI | -0.40% | -3.12% | History → |
| BRIDGEBIO PHARMA INC | BBIO | -0.70% | -2.75% | History → |
| ALLOGENE THERAPEUTICS INC | ALLO | 0.10% | -1.86% | Holders → |
| AGIOS PHARMACEUTICALS INC | AGIO | 0.16% | -1.85% | Holders → |
| KALVISTA PHARMACEUTICALS INC | KALV | 0.38% | -1.56% | Holders → |
| KRYSTAL BIOTECH | KRYS | -0.04% | -1.46% | History → |
| SAVARA INC | SVRA | -0.23% | -1.43% | Holders → |
Exited Positions Q1 2026
Positions present in the prior 13F-HR filing that no longer appear in Q1 2026.
| Company | Ticker | Last-Reported Portfolio Weight |
|---|---|---|
| AVIDITY BIOSCIENCES INC | SYN_05370A108 | 1.90% |
| ABIVAX S.A. | ABVX | 1.37% |
| RAPT THERAPEUTICS INC | SYN_75382E208 | 0.89% |
| TRAVERE THERAPEUTICS INC | TVTX | 0.25% |
| DESIGN THERAPEUTICS, INC. | DSGN | 0.13% |
| XILIO THERAPEUTICS INC | SYN_98422T100 | 0.10% |
Methodology & FAQ
How Frazier Life Sciences Management, L.P. Quarterly Changes Are Computed
Each row above is computed by joining the most recent 13F-HR filing for Frazier Life Sciences Management, L.P. against the immediately preceding quarterly filing for the same fund. Portfolio weights are normalized to exclude listed options for comparability. A complete description of the methodology — including how confidential treatment filings are handled and why share count rather than weight is the cleaner trading signal — is documented in the Methodology.
Which positions did Frazier Life Sciences Management, L.P. initiate in Q1 2026?
Frazier Life Sciences Management, L.P. established 4 new positions in Q1 2026: BIOCRYST PHARMACEUTICALS INC (BCRX, 0.98%), ACLARIS THERAPEUTICS INC (ACRS, 0.48%), MONTE ROSA THERAPEUTICS INC (GLUE, 0.42%), XILIO THERAPEUTICS INC (XLO, 0.09%).
Which existing positions saw the largest allocation increases for Frazier Life Sciences Management, L.P. in Q1 2026?
The largest portfolio-weight increases in existing positions were: MANNKIND CORP (MNKD, +-0.27% weight, +39.64% shares), IMMUNOCORE HOLDINGS PLC (IMCR, +0.02% weight, +25.99% shares), CYTOKINETICS INC (CYTK, +0.37% weight, +24.10% shares), PALVELLA THERAPEUTICS INC NE (PVLA, +0.80% weight, +22.15% shares), MIRUM PHARMACEUTICALS INC (MIRM, +3.84% weight, +13.02% shares), ACADIA PHARMACEUTICALS INC. (ACAD, +-0.11% weight, +10.87% shares), ERASCA INC (ERAS, +8.00% weight, +8.56% shares), DISC MEDICINE INC (IRON, +-0.46% weight, +7.53% shares).
Which positions did Frazier Life Sciences Management, L.P. fully exit in Q1 2026?
Frazier Life Sciences Management, L.P. fully exited 6 positions in Q1 2026: AVIDITY BIOSCIENCES INC (SYN_05370A108, last-reported weight 1.90%), ABIVAX S.A. (ABVX, last-reported weight 1.37%), RAPT THERAPEUTICS INC (SYN_75382E208, last-reported weight 0.89%), TRAVERE THERAPEUTICS INC (TVTX, last-reported weight 0.25%), DESIGN THERAPEUTICS, INC. (DSGN, last-reported weight 0.13%), XILIO THERAPEUTICS INC (SYN_98422T100, last-reported weight 0.10%).
Which existing positions saw the largest allocation reductions for Frazier Life Sciences Management, L.P. in Q1 2026?
The largest portfolio-weight reductions in positions kept open were: REVOLUTION MEDICINES INC (RVMD, -0.02% weight, -15.27% shares), AUTOLUS THERAPEUTICS LTD (AUTL, -0.09% weight, -3.79% shares), TREVI THERAPEUTICS INC (TRVI, -0.40% weight, -3.12% shares), BRIDGEBIO PHARMA INC (BBIO, -0.70% weight, -2.75% shares), ALLOGENE THERAPEUTICS INC (ALLO, 0.10% weight, -1.86% shares), AGIOS PHARMACEUTICALS INC (AGIO, 0.16% weight, -1.85% shares), KALVISTA PHARMACEUTICALS INC (KALV, 0.38% weight, -1.56% shares), KRYSTAL BIOTECH (KRYS, -0.04% weight, -1.46% shares), SAVARA INC (SVRA, -0.23% weight, -1.43% shares).
Do quarter-over-quarter 13F allocation changes constitute explicit trading signals?
No. Quarter-over-quarter changes reflect a combination of active trading and market price movement. A weight increase can result from price appreciation alone, without the manager adding shares. Share-count delta is the cleaner indicator of explicit trading activity.